TAE684 (NVP-TAE684)

Catalog No.S1108

TAE684 (NVP-TAE684) Chemical Structure

Molecular Weight(MW): 614.2

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.

Size Price Stock Quantity  
USD 160 In stock
USD 290 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) H3122 xenografts harboring the EML4-ALK translocation were treated with control vehicle or the ALK inhibitor, TAE-684, for 2 days; the tumors were excised and lysates were prepared. The TIMM results for the control and treated animals are shown. (B) H3122 cells were treated in the presence or absence of TAE-684 (100 nM) for 6 hours in the presence or absence of the indicated ligands [EGF (50 ng/mL), IGF1 (50 ng/mL), and HGF (50 ng/mL)]. Extracts were probed with the indicated antibodies.

    Cancer Res 2011 71, 4920-31. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (B) Dosage effects of TAE684 on phospho-Y1604 ALK expression of wild-type, H694R, and E1384K transfectants by Western blot analysis (top panel). Quantitative results of phospho-Y1604 ALK intensity are also (bottom panel).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

  • Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (C) Suppressive effects of TAE684 on H694R- and E1384K-induced tumors in vivo. Photographs and tumor growth curves are shown in the top and bottom panels, respectively (four mice per group).

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

    Therapeutic effects of ALK inhibitor TAE684 on H694R- and E1384K-mediated tumorigenesis of H1299 transfectants. (A) Dosage effects of TAE684 on H694R- and E1384K-induced cell proliferation measured with WST-1 activity. 

    Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck.

Purity & Quality Control

Choose Selective ALK Inhibitors

Biological Activity

Description TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.
Targets
ALK [1]
(Cell-free assay)
3 nM
In vitro

TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXJ[nRjUUN3ME2wMlAxODB4MEOg{txO M3eyXHNCVkeHUh?=
SF539 NXrabZk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfqTWM2OD1yLkCwNFU3PCEQvF2= NVrXXnlWW0GQR1XS
DEL NYXVeWhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT6TWM2OD1yLkCwNFkzPyEQvF2= NY\XUlZ2W0GQR1XS
NB1 NX\2eVhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y3fWlEPTB;MD6wNFE3OiEQvF2= NGnmdJRUSU6JRWK=
SR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMECyO|ch|ryP MoWzV2FPT0WU
KARPAS-299 NGfWNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljoTWM2OD1yLkCyN|g1KM7:TR?= MoDkV2FPT0WU
MHH-CALL-2 NYPJcFRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW4TWM2OD1yLkCyPVUzKM7:TR?= MYTTRW5ITVJ?
SU-DHL-1 NVjiPXQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\PTIkyUUN3ME2wMlA1QDZ3IN88US=> MVnTRW5ITVJ?
A4-Fuk M1LNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S2O2lEPTB;MD6wOVU3PSEQvF2= NInt[JVUSU6JRWK=
EW-1 MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMUCyOVYh|ryP MlyzV2FPT0WU
NOS-1 M2nsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTnS5NKSzVyPUCuNVAzQTRizszN NHTxdYhUSU6JRWK=
EW-16 NIe3[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\VS2lEPTB;MD6xNFU3QCEQvF2= M1XET3NCVkeHUh?=
TE-11 NYPQS45lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDjWpBzUUN3ME2wMlE3ODl4IN88US=> MY\TRW5ITVJ?
SW982 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv6OXFKSzVyPUCuNVY1PzhizszN MlWzV2FPT0WU
LAN-6 M2\sNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuwRXJKSzVyPUCuNVc1PDNizszN MWrTRW5ITVJ?
MZ1-PC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMUe4N|Uh|ryP NEmxTnhUSU6JRWK=
KS-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMUmzOFMh|ryP MXrTRW5ITVJ?
PSN1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEiz[YFKSzVyPUCuNVk3OzFizszN M1T2TXNCVkeHUh?=
LC-2-ad M{nwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfkPVYxUUN3ME2wMlE6Pjl{IN88US=> NG\YcHNUSU6JRWK=
COLO-320-HSR NH7PU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\1TWM2OD1yLkG5O|c3KM7:TR?= NYriU41MW0GQR1XS
OPM-2 NEPobYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMkK2Olkh|ryP NHOxRnZUSU6JRWK=
SK-NEP-1 NUTt[2RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HmcGlEPTB;MD6yN|UzPCEQvF2= MXHTRW5ITVJ?
ALL-PO M{jOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMkS1NlQh|ryP NUXrbY9IW0GQR1XS
CMK MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMkW1N{DPxE1? NW[2Soc2W0GQR1XS
NCI-H1648 MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMke4OVUh|ryP NXnBfXBSW0GQR1XS
SIG-M5 M4HIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMkmxOVkh|ryP M1rFWnNCVkeHUh?=
TGBC24TKB NIG5PVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfKb|dZUUN3ME2wMlMxOjF6IN88US=> NEPENZVUSU6JRWK=
DOHH-2 NIHlS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrkTWM2OD1yLkOxNlA1KM7:TR?= NWfqdWNQW0GQR1XS
NB69 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vmWmlEPTB;MD6zNVc5PyEQvF2= NH\4ZWhUSU6JRWK=
MFH-ino NHn3XY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HCT2lEPTB;MD6zNlUzOyEQvF2= MVfTRW5ITVJ?
KP-N-RT-BM-1 M4f4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwM{OxNlMh|ryP MoXnV2FPT0WU
MONO-MAC-6 NXzG[mpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPwZm1iUUN3ME2wMlM{OjlzIN88US=> M4XSenNCVkeHUh?=
ATN-1 Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwM{OzNFMh|ryP M1z1b3NCVkeHUh?=
NTERA-S-cl-D1 NFnKd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwM{OzPVYh|ryP NWT3ZlFsW0GQR1XS
L-540 NHjwXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jMSWlEPTB;MD6zOlk5QCEQvF2= NG\mOHFUSU6JRWK=
GB-1 MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHvNXFwUUN3ME2wMlM5QDZ5IN88US=> NHvSc2JUSU6JRWK=
MV-4-11 M1LWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jXdWlEPTB;MD6zPVQ1PiEQvF2= NH3Vb3NUSU6JRWK=
KG-1 MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\xZVRKSzVyPUCuN|k2PjFizszN MWTTRW5ITVJ?
OVCAR-4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml23TWM2OD1yLkSwOVY6KM7:TR?= NXOzVIpOW0GQR1XS
NEC8 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD1TWM2OD1yLkSxNlkzKM7:TR?= MlrlV2FPT0WU
SK-MM-2 NHfZPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrRe3pKSzVyPUCuOFE3ODlizszN MonQV2FPT0WU
TE-8 MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\XcI1EUUN3ME2wMlQzQDhizszN NIm4NoxUSU6JRWK=
697 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H6OWlEPTB;MD60N|IyPSEQvF2= M2\sfnNCVkeHUh?=
NB14 MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljyTWM2OD1yLkSzPFI3KM7:TR?= M{XFdHNCVkeHUh?=
GDM-1 NY\BNmRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIewUo1KSzVyPUCuOFcyOTZizszN NHTqZZRUSU6JRWK=
HUTU-80 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7ablVKSzVyPUCuOFc{PzVizszN NGfmV5hUSU6JRWK=
HL-60 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwNEixOFIh|ryP NET3fXlUSU6JRWK=
OCI-AML2 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzmTWM2OD1yLkS4N|I5KM7:TR?= NXjVc2ZLW0GQR1XS
ML-2 NHHTXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXrO2xmUUN3ME2wMlQ6ODNzIN88US=> MXzTRW5ITVJ?
ES4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwNEmxNFkh|ryP NV\XOWI{W0GQR1XS
NCI-H747 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITW[VVKSzVyPUCuOFk5QSEQvF2= MnnDV2FPT0WU
RL95-2 Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j0dGlEPTB;MD61NFEyOiEQvF2= MlPQV2FPT0WU
TE-15 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC4TWM2OD1yLkWxNVI1KM7:TR?= M4P0XHNCVkeHUh?=
TE-12 NFTxU|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPycmtjUUN3ME2wMlU{OzR7IN88US=> M1r5SHNCVkeHUh?=
LB1047-RCC NGfLd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv6NGNKSzVyPUCuOVQ2PDlizszN M1[xTHNCVkeHUh?=
LB831-BLC MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwNUWwNlMh|ryP MkT0V2FPT0WU
NCI-H1355 M3vqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XnRmlEPTB;MD61OVE5PCEQvF2= NWS1eFJZW0GQR1XS
CTV-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF20TXJKSzVyPUCuOVU3OjRizszN Mn;kV2FPT0WU
RXF393 NWHEU25tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn1PZk3UUN3ME2wMlU2Pzl2IN88US=> MWXTRW5ITVJ?
SW872 NFzSSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHyxN4FKSzVyPUCuOVY4OjRizszN NYDSPHN1W0GQR1XS
MPP-89 NYroO5BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HlZWlEPTB;MD61O|g5PCEQvF2= MnGzV2FPT0WU
RPMI-8226 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NECzSnRKSzVyPUCuOlM2OjZizszN MVzTRW5ITVJ?
LS-1034 MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwNkO1PEDPxE1? NVKwRlFOW0GQR1XS
SJSA-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfLTWM2OD1yLk[zO|I2KM7:TR?= NVPpbHpoW0GQR1XS
HOP-62 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNkWwN|Mh|ryP NGe2W4VUSU6JRWK=
KGN M2frVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLIR|E2UUN3ME2wMlY3OTZ6IN88US=> MXHTRW5ITVJ?
D-336MG M4nmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XiNWlEPTB;MD62OlE3QSEQvF2= MVjTRW5ITVJ?
LS-411N MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwNke0OlIh|ryP MYjTRW5ITVJ?
TE-1 NUTFV2xxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLHT5VbUUN3ME2wMlY6ODd2IN88US=> MYjTRW5ITVJ?
LB996-RCC NET1VYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTH[pJ3UUN3ME2wMlY6Ozh7IN88US=> NWTX[lBQW0GQR1XS
TE-10 MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe2[GdKSzVyPUCuO|E1QTZizszN NIrOW2JUSU6JRWK=
NCI-SNU-16 MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH6T3hXUUN3ME2wMlczPjZ2IN88US=> M1zleXNCVkeHUh?=
ES8 MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHoT5FKSzVyPUCuO|Q6PzVizszN MkG2V2FPT0WU
COLO-800 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwN{[2PVUh|ryP MVLTRW5ITVJ?
ES6 NF7EcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW3W5ozUUN3ME2wMlc4PTV7IN88US=> NEPpcohUSU6JRWK=
L-363 NHrDOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDvblhKSzVyPUCuPFI{PzVizszN NGfubWNUSU6JRWK=
NMC-G1 NH3CTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\mTWM2OD1yLkizNlM{KM7:TR?= M2XObXNCVkeHUh?=
LU-134-A NITZZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:3TWM2OD1yLkizPVEzKM7:TR?= MonLV2FPT0WU
SF268 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVThfnVHUUN3ME2wMlg1ODR{IN88US=> NXniUpFoW0GQR1XS
KARPAS-45 M4\JWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnVcpB3UUN3ME2wMlg1OjZ|IN88US=> NFzsZmtUSU6JRWK=
TGW M{i3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS5NI5KSzVyPUCuPFU5PjNizszN MYrTRW5ITVJ?
CHP-126 MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XKU2lEPTB;MD64OVk2PyEQvF2= NFfqOWZUSU6JRWK=
MOLT-16 NXXVPZk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwOEe1PFkh|ryP MlHnV2FPT0WU
LB771-HNC M1\EUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13MUWlEPTB;MD64PVc2PyEQvF2= NFT0cYFUSU6JRWK=
NALM-6 NFXtS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13HXGlEPTB;MD65NFc{QSEQvF2= MXfTRW5ITVJ?
GCIY NXnpeWZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwOUW1NlYh|ryP NHXkXlhUSU6JRWK=
IST-MES1 NVH1RZFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e1UGlEPTB;MD65PFgzPCEQvF2= MorsV2FPT0WU
LB2241-RCC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[2RY5KSzVyPUCuPVg5PCEQvF2= MWfTRW5ITVJ?
BL-70 NXPJTWNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDS[oZKSzVyPUCuPVk2OzVizszN MnrqV2FPT0WU
NB17 NWG2WYxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUOxWY9nUUN3ME2xMlAxPjN7IN88US=> MlPBV2FPT0WU
LXF-289 NV6zOlU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnweosxUUN3ME2xMlA{ODd4IN88US=> MX7TRW5ITVJ?
TK10 M2SzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPkeoFyUUN3ME2xMlA2ODZ|IN88US=> MWrTRW5ITVJ?
K5 NXz0cm1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwME[yO|Qh|ryP MnL1V2FPT0WU
NCI-H716 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LNfGlEPTB;MT6wO|I2QSEQvF2= NXXaT2F5W0GQR1XS
HCE-T MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDYTWM2OD1zLkC4PFE6KM7:TR?= M3nPT3NCVkeHUh?=
GI-1 Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwMEm3PVgh|ryP MV3TRW5ITVJ?
KARPAS-422 NWTKcHJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLpS4tKSzVyPUGuNVAxOjJizszN MmDKV2FPT0WU
TE-9 NVH3PWxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T6T2lEPTB;MT6xNVMzQCEQvF2= NFLQS|BUSU6JRWK=
SF126 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3Y[3dKSzVyPUGuNVE2PjhizszN M{CxOXNCVkeHUh?=
BB30-HNC MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwMUOxNVIh|ryP NVrWWVFRW0GQR1XS
NCI-H1304 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFwMUOzN|gh|ryP MXXTRW5ITVJ?
HEL NWPT[VNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFwMUS4PVUh|ryP NV;JflNHW0GQR1XS
HAL-01 NHL2RYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LWWmlEPTB;MT6xOVI5OyEQvF2= NXzwb|U3W0GQR1XS
SK-LMS-1 M4i4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:4TWM2OD1zLkG1PVc1KM7:TR?= MnnzV2FPT0WU
SW954 M17Od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULaN|dpUUN3ME2xMlE6PTZ5IN88US=> MULTRW5ITVJ?
D-283MED MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjKTIdKSzVyPUGuNlI{PzlizszN MnLyV2FPT0WU
NCI-H1882 MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HGcGlEPTB;MT6yN|g6KM7:TR?= NWHtS25KW0GQR1XS
GI-ME-N MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;mUVBSUUN3ME2xMlI2OjB6IN88US=> NUfWUFJMW0GQR1XS
SK-PN-DW NYOybWN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;LUWlEPTB;MT6yOlM1QCEQvF2= Mn3FV2FPT0WU
C2BBe1 M{TUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET4WXdKSzVyPUGuNlkyOTdizszN MXTTRW5ITVJ?
A704 NVjnc2RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH1TplKSzVyPUGuN|I3QDlizszN NYHqXo9kW0GQR1XS
KALS-1 M{fi[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTFwM{SwPEDPxE1? NEHuUmhUSU6JRWK=
ETK-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPiOJNYUUN3ME2xMlM1PDh7IN88US=> M3TycXNCVkeHUh?=
LB647-SCLC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G2cGlEPTB;MT6zOFk5PiEQvF2= MXnTRW5ITVJ?
OCUB-M NX36dIFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPjTWM2OD1zLkO2NVQ{KM7:TR?= MVvTRW5ITVJ?
NCI-H720 NV3PeHlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTrUWRKSzVyPUGuN|Y{PzhizszN MUXTRW5ITVJ?
NB13 NXPEepppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\4cWRoUUN3ME2xMlM4Ojl|IN88US=> NYnGVXhxW0GQR1XS
GR-ST NUfaTYRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nrXWlEPTB;MT6zPFc2PyEQvF2= MlGyV2FPT0WU
DU-4475 NHO0dnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfLOZc{UUN3ME2xMlQ2QDV|IN88US=> MXzTRW5ITVJ?
HCC2157 MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXKdWhpUUN3ME2xMlQ3PjV7IN88US=> NW\sPIVHW0GQR1XS
RKO M4TaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwNEm5NlIh|ryP MVnTRW5ITVJ?
LS-123 MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwNUG1PVQh|ryP MYfTRW5ITVJ?
NCI-H69 MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwNUW4NVEh|ryP MlPVV2FPT0WU
SW962 MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLzTWM2OD1zLkW2NVMh|ryP MUTTRW5ITVJ?
PF-382 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwNU[5OkDPxE1? NUTDSZR6W0GQR1XS
A101D NFXRRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3STWM2OD1zLkW3NVE{KM7:TR?= MWHTRW5ITVJ?
NB10 M{\EZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTEbFhJUUN3ME2xMlU4Ozl{IN88US=> M4HUUXNCVkeHUh?=
NB5 NVm0PHlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUewcId4UUN3ME2xMlU5PDd4IN88US=> NXnxU2E{W0GQR1XS
HCE-4 Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFwNkC4OUDPxE1? NHvDS5pUSU6JRWK=
HT-144 M4DtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTBTWM2OD1zLk[zNVkh|ryP M2DnV3NCVkeHUh?=
NCI-H524 M{jOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnEdGltUUN3ME2xMlY1OzB5IN88US=> MYDTRW5ITVJ?
NKM-1 NFXrR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLueFB{UUN3ME2xMlY5PjZizszN NG\vZoFUSU6JRWK=
KURAMOCHI M4Tsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[2TWM2OD1zLk[5OVc{KM7:TR?= M4PES3NCVkeHUh?=
NCI-H187 M2T4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr3TWM2OD1zLkewNFM3KM7:TR?= NGraOHFUSU6JRWK=
U-266 NGjVU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorvTWM2OD1zLkezPFQzKM7:TR?= MnfBV2FPT0WU
BL-41 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DY[2lEPTB;MT63OlI4OiEQvF2= MXnTRW5ITVJ?
SK-N-DZ NVv2S|ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\md|ZHUUN3ME2xMlc5OzB7IN88US=> NGn5N|NUSU6JRWK=
Daudi M4nlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3POeGlEPTB;MT63PFk3PyEQvF2= NUX1S|FKW0GQR1XS
CPC-N M1fsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;1OpBOUUN3ME2xMlg2ODl4IN88US=> M1vP[HNCVkeHUh?=
EM-2 M2C1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn1TFlKSzVyPUGuPFUyKM7:TR?= MYrTRW5ITVJ?
HCC1187 NH[4[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;Tc|g4UUN3ME2xMlg3OjRzIN88US=> NHvPU|VUSU6JRWK=
LP-1 MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fjZWlEPTB;MT64O|E1OyEQvF2= MkTuV2FPT0WU
CAS-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\uUGFKSzVyPUGuPVgzQTlizszN MonPV2FPT0WU
NB7 M{XVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTJTWM2OD1{LkCwOVU2KM7:TR?= M3jOTXNCVkeHUh?=
VA-ES-BJ Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zXZ2lEPTB;Mj6wNVUyOyEQvF2= NULUNoRVW0GQR1XS
SNU-C2B NF\4NHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\U[|NKSzVyPUKuNFM{PTFizszN M4n1XXNCVkeHUh?=
LOXIMVI NWPQW|VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonlTWM2OD1{LkC2O|g3KM7:TR?= MlHjV2FPT0WU
NCI-H1581 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nLTWlEPTB;Mj6xNVU2QSEQvF2= MVfTRW5ITVJ?
IST-SL2 NHS4c5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXzTWM2OD1{LkGyOFQ2KM7:TR?= NWq3S3VOW0GQR1XS
NOMO-1 NEPhNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfhfJpKSzVyPUKuNVc3QDNizszN NWPrd2pYW0GQR1XS
TE-6 NGjGZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHEW3VKSzVyPUKuNVkxPSEQvF2= MoPZV2FPT0WU
NCI-H526 Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHQeIhKSzVyPUKuNVkyPDFizszN NFr4b3pUSU6JRWK=
MSTO-211H M3XGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LhemlEPTB;Mj6yNFA1OSEQvF2= NFL1Z3lUSU6JRWK=
LS-513 NGTnfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH60eo9KSzVyPUKuNlIzPjlizszN NVnZ[oZ6W0GQR1XS
NCI-SNU-1 NYPPNmpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJwM{OyOVYh|ryP NF35PWdUSU6JRWK=
BB65-RCC M{TlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTtTY1SUUN3ME2yMlM4PDl|IN88US=> MWTTRW5ITVJ?
GT3TKB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJwM{m5O|Ih|ryP NH;Jco5USU6JRWK=
OS-RC-2 NX:5[GpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPmW|dEUUN3ME2yMlQzOzRzIN88US=> MYrTRW5ITVJ?
NCI-H2126 NHfXV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJwNEO2O|Qh|ryP M1X5ZXNCVkeHUh?=
SK-UT-1 NXuxXGVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorETWM2OD1{LkS3OFY4KM7:TR?= MY\TRW5ITVJ?
DMS-114 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJwNkG1NlQh|ryP NFHy[JhUSU6JRWK=
ONS-76 NH;UNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X0S2lEPTB;Mj62N|Y1OSEQvF2= MnzWV2FPT0WU
8-MG-BA M{n4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPxTWM2OD1{Lk[1OFE1KM7:TR?= MWrTRW5ITVJ?
BOKU MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLuZXBQUUN3ME2yMlczPzZ2IN88US=> Ml75V2FPT0WU
LAMA-84 MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJwN{m5NVIh|ryP NYLWVWpEW0GQR1XS
ES1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHnbZp5UUN3ME2yMlgyQDB2IN88US=> NWXOZ4tnW0GQR1XS
NCI-H1395 MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnhTWM2OD1{LkiyNFEzKM7:TR?= M37GN3NCVkeHUh?=
A388 MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7FeWdKSzVyPUKuPVYyPyEQvF2= NF\RXJNUSU6JRWK=
NCCIT NFfIOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLWTWM2OD1|LkC4PFYzKM7:TR?= M2\nOXNCVkeHUh?=
HD-MY-Z M4XlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvYeJZKSzVyPUOuNVMzODNizszN MWPTRW5ITVJ?
NCI-H510A NEL0SnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P1SWlEPTB;Mz6xPFk1OyEQvF2= MlvxV2FPT0WU
NCI-N87 NVy3W2ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnZTWM2OD1|LkKwNFIh|ryP NVvJSVBwW0GQR1XS
SCLC-21H NULiN2Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNwMk[4OVkh|ryP M1TtPHNCVkeHUh?=
SH-4 NHnyN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;WTWM2OD1|LkK4O|k4KM7:TR?= NUnScpQ3W0GQR1XS
QIMR-WIL MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPXTWM2OD1|LkOyPFQ6KM7:TR?= M2HMXXNCVkeHUh?=
KM12 MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr6bFRvUUN3ME2zMlM{PTR2IN88US=> NXvWZ2JYW0GQR1XS
ST486 NFLzdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHVdpJ2UUN3ME2zMlU{QDh|IN88US=> NGSyR3BUSU6JRWK=
HC-1 NVHnRlIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXaVIxKSzVyPUOuOlIxOjhizszN NFXOOFBUSU6JRWK=
BV-173 NILPVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3DU5VKSzVyPUOuOlQxQDhizszN NUPTPG1IW0GQR1XS
EW-24 Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDueHJKSzVyPUOuOlY1OzRizszN NXH1dXZZW0GQR1XS
LU-65 MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7sNYNKSzVyPUOuOlg4OSEQvF2= NE\lZ2FUSU6JRWK=
ECC4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\KTWM2OD1|Lke3OVYh|ryP M2rESnNCVkeHUh?=
ARH-77 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTRwMUGwOlch|ryP M1fpdnNCVkeHUh?=
BC-3 MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTRwMUOwOlgh|ryP MmfLV2FPT0WU
SNB75 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTRwMk[xPUDPxE1? MUTTRW5ITVJ?
MEG-01 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG4TWM2OD12LkK3OFE6KM7:TR?= MkTiV2FPT0WU
NCI-H1417 NIric4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHFTWM2OD12LkK4OFQ{KM7:TR?= MYrTRW5ITVJ?
MDA-MB-134-VI NIPDVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTRwM{C2NFEh|ryP MXjTRW5ITVJ?
Becker Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTRwNEezN|Yh|ryP M4XIV3NCVkeHUh?=
DMS-153 MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r4emlEPTB;ND62OlQ4PSEQvF2= M1f1NnNCVkeHUh?=
TGBC1TKB MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTRwNki1NVUh|ryP M{\JT3NCVkeHUh?=
EW-3 M{LYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTRwN{[yOFgh|ryP MXHTRW5ITVJ?
KE-37 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;lZWlEPTB;ND64OlE6PiEQvF2= NWG5[HNOW0GQR1XS
NCI-H23 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkOzTWM2OD12Lki3NlI4KM7:TR?= NWTqO2lVW0GQR1XS
MC116 M4\SeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LWOmlEPTB;ND65OFEzPiEQvF2= MorxV2FPT0WU
NH-12 NImzNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHDcXZKSzVyPUSuPVY1OzlizszN MXTTRW5ITVJ?
CTB-1 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTRwOUe3NlEh|ryP MYrTRW5ITVJ?
KM-H2 M2OzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTVwMEWzNlMh|ryP MnnIV2FPT0WU
MOLT-4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzOfHBKSzVyPUWuNVE5OyEQvF2= NEHVdo5USU6JRWK=
NCI-H2141 M1TPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG4foU6UUN3ME21MlE1OjZ6IN88US=> NHvDd2JUSU6JRWK=
EB-3 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3LTWM2OD13LkG3OVA1KM7:TR?= MUfTRW5ITVJ?
NCI-H1522 M4TQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTVwMk[zNlIh|ryP Mn\qV2FPT0WU
MRK-nu-1 MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT0S|l3UUN3ME21MlQ{PjN|IN88US=> NH\qe3lUSU6JRWK=
no-11 NYGwXHRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDmTWM2OD13LkS3NFg4KM7:TR?= MnfHV2FPT0WU
CESS Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTZTWM2OD13LkW4NFM1KM7:TR?= MU\TRW5ITVJ?
KMOE-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\RUHJKSzVyPUWuOVg3PTlizszN M2S0b3NCVkeHUh?=
REH Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;yTWM2OD14LkK1OlE5KM7:TR?= M1\2S3NCVkeHUh?=
KU812 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTZwNEK3PVEh|ryP NHvUfHNUSU6JRWK=
SK-N-FI NXLre4RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH5VJpKSzVyPU[uOlA3PzRizszN MVfTRW5ITVJ?
MMAC-SF MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHMPWlrUUN3ME23MlA3PDl{IN88US=> NIG2XnNUSU6JRWK=
RCC10RGB NG\5WnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTPWGN4UUN3ME23MlIzQTd5IN88US=> NYTLc3UxW0GQR1XS
NCI-H322M NULtVJJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPmO2dKSzVyPUeuN|M{OzVizszN M2HwSnNCVkeHUh?=
NB6 NYfLW3BZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTdwNUS4PVkh|ryP M4P5V3NCVkeHUh?=
MN-60 NX3Z[2VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml33TWM2OD15Lk[5NlE2KM7:TR?= NIjtUnZUSU6JRWK=
NCI-H1092 M1q1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRThwMEG3N|Qh|ryP NV34TJcxW0GQR1XS
EKVX MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRThwNEewOlYh|ryP M3vjc3NCVkeHUh?=
D-263MG NXzGfoRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7McI85UUN3ME24MlU2Ozl4IN88US=> MmXtV2FPT0WU
NCI-H209 NYnUeIJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRThwNkSwNFYh|ryP MUjTRW5ITVJ?
IST-SL1 NWT1Wo9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRThwOEm4PVIh|ryP MW\TRW5ITVJ?
ACN M3fTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i2eGlEPTB;OT6xPVE2PyEQvF2= MWLTRW5ITVJ?
MHH-PREB-1 M33CUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj5[GpyUUN3ME25MlIyOjF7IN88US=> M1foPHNCVkeHUh?=
EW-11 MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTlwNkWzPVYh|ryP MWXTRW5ITVJ?
KASUMI-1 NXLmVY84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK2TWM2OD17Lke4O|ch|ryP MmXUV2FPT0WU
KINGS-1 NIniOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[4WmF4UUN3ME2xNE4zOzR5IN88US=> M2\pUnNCVkeHUh?=
EVSA-T M1jRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17ySWlEPTB;MUCuN|E6OiEQvF2= MlK5V2FPT0WU
DSH1 MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFyLkO5O|Ih|ryP MkjEV2FPT0WU
COLO-824 NVnCXWpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT0TWM2OD1zMD64OlY6KM7:TR?= MnnnV2FPT0WU
K052 NV7EU4VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDsTWM2OD1zMD65N|IzKM7:TR?= M1\BbHNCVkeHUh?=
SK-MEL-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljETWM2OD1zMD65PVM6KM7:TR?= NWfoUJJtW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]

Protocol

Kinase Assay:[1]
+ Expand

In vitro Enzyme Assays.:

All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.
Cell Research:[1]
+ Expand
  • Cell lines: Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
  • Concentrations: 1 nM-10 μM
  • Incubation Time: 2–3 days
  • Method: Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
  • Formulation: Resuspended in 10% 1-methyl-2-pyrrolidinone/90% polyethylene glycol 300 solution
  • Dosages: 1, 3, and 10 mg/kg
  • Administration: Once daily by oral gavage for 3 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (4.88 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol, pH 4
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 614.2
Formula

C30H40ClN7O3S

CAS No. 761439-42-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ALK Signaling Pathway Map

ALK Inhibitors with Unique Features

Related ALK Products4

Tags: buy TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) supplier | purchase TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) cost | TAE684 (NVP-TAE684) manufacturer | order TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID